The FDA approved a new drug to treat Alzheimer’s, but Medicare won’t always pay for it – A doctor explains what researchers know about Biogen’s Aduhelm || by Andrew Williams :: The Conversation

Medicare finalized its decision to restrict its coverage of Aduhelm, Biogen’s new Alzheimer’s disease drug, on April 8, 2022.The decision means only patients who have enrolled in clinical trials , will receive Medicare coverage for Aduhelm which goes by the generic drug name of Aducanumab. Read more